An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Completed · Phase 2

Conditions studied: Prostate Cancer, Melanoma, Non-Hodgkin's Lymphoma

In brief

This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the previous study.

Key facts

Study ID

NCT00818480

Run by

Astellas Pharma Inc

People needed

10

Starts

2006-02-01

Expected to finish

2012-08-01

Last updated by the study team

2015-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completed a Phase I or II YM155 study with at least stable disease and continues to meet the criteria as stated in the previous YM155 study that allows for additional treatment with YM155
• Lack of progression based on the most recent radiological imaging, biochemical assessments and/or physical examination
• Negative pregnancy test result (females of child-bearing potential)

You may not qualify if…

• More than 21 days (or 14 days depending on the study of origin) between the time the last infusion of YM155 was stopped in the previous study and the proposed start of the first infusion in this study

Where it is running

• Institute for Drug Development — San Antonio, Texas, United States
• South Texas Accelerated — San Antonio, Texas, United States
• Huntsman Cancer Hospital — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.